Novogenia AG, an international healthcare company specializing in human genetics and personalized products, has announced the U.S. market launch of its new MGT Plus methylation test. This launch, in collaboration with U.S. partner 10X Health, aims to expand their joint product pipeline and strengthen their international collaboration in genetic analysis and longevity. The test is designed to provide a more comprehensive understanding of methylation, a fundamental biochemical process involved in numerous metabolic and regulatory functions in the human body.
Methylation plays a critical role in the function and processing of biological molecules, including vitamins and neurotransmitters. While commercially available tests typically analyze a limited number of genes, MGT Plus covers 27 genes, offering a broader scope of analysis. This enables a more complete picture of methylation processes across six interconnected biological pathways: energy and nutrient metabolism, stress and neurotransmitter regulation, vascular health, immune function, and cellular health. The expanded analysis provides deeper insights into key biochemical processes, allowing for more precise and personalized prevention and health strategies.
Dr. Daniel Wallerstorfer, CEO of Novogenia AG, emphasized the significance of the new test: "With MGT Plus, we are enabling a more comprehensive understanding of biochemical methylation processes. The significantly expanded scope of analysis provides deeper insights into genetic factors involved in methylation-related metabolic pathways in the body, creating new opportunities for more personalized prevention and health strategies. Our close collaboration with our U.S. partner 10X Health underscores our commitment to making scientific innovations accessible internationally and actively advancing personalized approaches to preventive health."
The launch comes at a time when the global direct-to-consumer testing market is experiencing robust growth. In 2025, the market was valued at approximately $4.7 billion and is projected to reach more than $16.0 billion by 2033. Genetic testing constitutes the largest segment, accounting for over 40% of the market. North America leads the sector, representing around 50% of the global market volume in 2025. This growth is driven by increasing consumer interest in personalized health information, prevention, and tailored health services.
Novogenia's expansion into the U.S. market with MGT Plus underscores its strategic focus on leveraging genetic insights to offer personalized health solutions. By partnering with 10X Health, Novogenia aims to make its innovative testing accessible to a broader audience, potentially influencing how individuals approach preventive health and wellness.
